8-K Featured Impact 6/10 Debt/Credit Facility

$EW · Edwards Lifesciences Corp

November 19, 2026 · AI-analyzed SEC filing · Verify material figures against the official SEC.gov filing

On November 19, 2026, Edwards Lifesciences entered into an Amended and Restated Five Year Credit Agreement, replacing its July 15, 2022 facility. The new agreement provides a five-year $750 million multi-currency unsecured revolving credit facility, expandable by up to $375 million, maturing November 19, 2031. Borrowings bear interest at SOFR or base rate plus a margin tied to leverage ratio or debt ratings. No amounts have been borrowed as of the filing date.

  • New facility is a $750M multi-currency unsecured revolver.
  • Maturity extended to November 19, 2031.
  • Facility can be increased by up to $375M with lender agreement.
  • Interest margin is based on leverage ratio or debt ratings.
  • No amounts borrowed as of the filing date.

Markets closed — no regular-session reaction yet; extended-hours move not captured here.

Routine balance-sheet refresh that extends maturity and improves terms, with no immediate borrowing.

_Not applicable._

Customary covenants include a maximum leverage ratio; an event of default could accelerate all obligations.

$EW

Get filings like this before the market reacts.

Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.

Start your free trial →